Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies

被引:0
作者
Michael Rainone
Tanya Siddiqi
机构
[1] City of Hope,Department of Hematology and Medical Oncology
[2] City of Hope,Department of Hematology & Hematopoietic Cell Transplantation
来源
Current Hematologic Malignancy Reports | 2022年 / 17卷
关键词
Chronic lymphocytic leukemia; Small lymphocytic lymphoma; Ibrutinib; Acalabrutinib; Venetoclax; Chimeric antigen receptor (CAR) T cell;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:39 / 45
页数:6
相关论文
共 43 条
[1]  
Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30
[2]  
Miller KD(2016)2016 US lymphoid malignancy statistics by World Health Organization subtypes CA Cancer J Clin 66 443-459
[3]  
Jemal A(2012)Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease? Cancer J 18 396-403
[4]  
Teras LR(2011)State of the art treatment of chronic lymphocytic leukaemia Blood Rev 25 1-9
[5]  
Santos FP(2016)Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial Blood 127 208-215
[6]  
O'Brien S(2020)Treatment of chronic lymphocytic leukemia N Engl J Med 383 460-473
[7]  
Hallek M(2015)Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia N Engl J Med 373 2425-2437
[8]  
Pflug N(2008)Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 5446-5456
[9]  
Fischer K(2014)Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 371 213-223
[10]  
Burger JA(2016)Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study Lancet Oncol 17 1409-1418